Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 22454421

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2012 Jun 20
First author
Younes A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2012 Jun 20;30(18):2171-2. doi: 10.1200/JCO.2011.39.6416.
    note
    Source null
    related pmid
    22547611
    relationship
    Comment in
  2. citation
    Clin Adv Hematol Oncol. 2012 Jul;10(7):468-71.
    note
    Source null
    related pmid
    22895289
    relationship
    Comment in

Authors and identifiers

  1. name
    Younes A
    type
    Author
  2. name
    Gopal AK
    type
    Author
  3. name
    Smith SE
    type
    Author
  4. name
    Ansell SM
    type
    Author
  5. name
    Rosenblatt JD
    type
    Author
  6. name
    Savage KJ
    type
    Author
  7. name
    Ramchandren R
    type
    Author
  8. name
    Bartlett NL
    type
    Author
  9. name
    Cheson BD
    type
    Author
  10. name
    de Vos S
    type
    Author
  11. name
    Forero-Torres A
    type
    Author
  12. name
    Moskowitz CH
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Younes A
    type
    Author
  2. name
    Gopal AK
    type
    Author
  3. name
    Smith SE
    type
    Author
  4. name
    Ansell SM
    type
    Author
  5. name
    Rosenblatt JD
    type
    Author
  6. name
    Savage KJ
    type
    Author
  7. name
    Ramchandren R
    type
    Author
  8. name
    Bartlett NL
    type
    Author
  9. name
    Cheson BD
    type
    Author
  10. name
    de Vos S
    type
    Author
  11. name
    Forero-Torres A
    type
    Author
  12. name
    Moskowitz CH
    type
    Author
bibliography ids
  1. nci-bib-6df86452c50ca142aa730d2f
book metadata
content sha256
bc7f233e647fd13714448ec50a89be982269dd92e1aea38d5cc4a0594420d137
document type
citation
dois
  1. 10.1200/JCO.2011.38.0410
electronic publication date
display
2012 Mar 26
precision
day
year
2012
evidence scope
bibliographic_metadata_only
id
pubmed:22454421
immutable id
pubmed:22454421@bc7f233e647fd13714448ec50a89be982269dd92e1aea38d5cc4a0594420d137
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
18
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
2183-9
volume
30
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2012 Jun 20;30(18):2171-2. doi: 10.1200/JCO.2011.39.6416.
    note
    Source null
    related pmid
    22547611
    relationship
    Comment in
  2. citation
    Clin Adv Hematol Oncol. 2012 Jul;10(7):468-71.
    note
    Source null
    related pmid
    22895289
    relationship
    Comment in
outcomes validated
false
pmid
22454421
provenance
batch id
c95be1d0b8cf19942816
provider
NCBI PubMed ESummary
record sha256
53892ff51697ec07a3163df9cb91514c5e2102a3a85d9576da0d553b0ef50c7d
response sha256
a96bb680a8f3690267e009557d1b07aab71455ba44aeba18695d98a3eeb5fcf2
retrieved at
2026-09-09T23:46:47.691937+00:00
publication date
display
2012 Jun 20
precision
day
year
2012
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/22454421/
title
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Preserved source evidence · Not medical advice